Key Highlights

  • Valion Bio (NASDAQ:VBIO) traded at USD 0.7510, down 10.60%, in pre-market trading on Tuesday, October 27, 2026. No company-specific announcement dated on or just before that day accompanied the move.
  • For the quarter ended June 30, 2026, the company reported a net loss of USD 7,103 thousand, or USD 2.17 per share, and cash and cash equivalents of USD 2,108 thousand, down from USD 12,645 thousand.
  • The company completed a 1-for-25 reverse stock split on Monday, August 31, 2026 and regained Nasdaq minimum bid price compliance on Tuesday, September 22, 2026, after the split.
  • Pre-market prices are thinly traded and can change before the open at 9:30 a.m. ET. The latest quarterly filing states substantial doubt about the ability of the company to continue as a going concern.

The Pre-Market Move and Its Catalyst

Valion Bio (NASDAQ:VBIO), formerly Tivic Health Systems, a biotechnology company that licenses Entolimod for acute radiation syndrome and operates a contract development and manufacturing subsidiary named Velocity Bioworks, traded at USD 0.7510, down 10.60%, in a pre-market snapshot on Tuesday, October 27, 2026. No company-specific announcement dated on or just before that day accompanied the move. The most recent release of the company, dated Thursday, October 15, 2026, reported that a partnership with LarmorBio on nuclear magnetic resonance technology had reached an initial feasibility milestone. The decline appears consistent with thin liquidity and with a share price that has again moved below the USD 1.00 level after the split, which is an inference.

How the Latest Results and Cash Position Frame the Move

The Form 10-Q of Valion Bio (NASDAQ:VBIO) for the quarter ended June 30, 2026 shows no revenue line and a net loss of USD 7,103 thousand, or USD 2.17 per share, against USD 13,305 thousand, or USD 4.59 per share, for the six months. Cash and cash equivalents were USD 2,108 thousand at June 30, 2026, against USD 12,645 thousand at Wednesday, December 31, 2025, and the filing states substantial doubt about going concern. Common shares outstanding rose to 22,189,739 at Thursday, August 13, 2026, before the 1-for-25 split, as preferred stock converted and warrants were exercised. The company named Dean Zikria interim chief executive officer on Wednesday, September 23, 2026, and the Ukraine Ministry of Health advanced its Entolimod review to technical assessment on Thursday, August 13, 2026.

Risks and What to Watch

The bull reading for Valion Bio (NASDAQ:VBIO) is that a first regulatory approval of Entolimod in Ukraine, which the company says could come as early as the fourth quarter of 2026, and the manufacturing subsidiary could create a revenue base. The bear reading is that cash of USD 2,108 thousand at June 30, 2026 is small against a quarterly loss of USD 7,103 thousand, so further equity financing appears likely. Three risks stand out: dilution from that financing, renewed minimum bid price non-compliance and uncertainty over the timing and outcome of the Ukrainian review. Investors should watch any financing announcement, the quarterly report for the period ended Wednesday, September 30, 2026, the Ukrainian regulatory decision and the Federal Reserve decision on Wednesday, October 28, 2026.

Where Things Stand

The answer is that Valion Bio (NASDAQ:VBIO) fell in pre-market trading without a dated company announcement, and whether the share holds support depends on financing, thin liquidity and a going concern warning. The key number is USD 0.7510, a decline of 10.60% in the pre-market snapshot. The next catalysts are any financing, the Ukrainian review of Entolimod and the Federal Reserve decision on Wednesday, October 28, 2026, which follows the rate rise to 4.00% from 3.75% on Wednesday, September 16, 2026. Pre-market prices are snapshots and can change, and this is not investment advice.